CA2992509C - Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases - Google Patents

Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases

Info

Publication number
CA2992509C
CA2992509C CA2992509A CA2992509A CA2992509C CA 2992509 C CA2992509 C CA 2992509C CA 2992509 A CA2992509 A CA 2992509A CA 2992509 A CA2992509 A CA 2992509A CA 2992509 C CA2992509 C CA 2992509C
Authority
CA
Canada
Prior art keywords
inflammatory disorders
treating proliferative
tfr antibodies
antibodies
tfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2992509A
Other languages
English (en)
French (fr)
Other versions
CA2992509A1 (en
Inventor
Pierre Launay
Coralie Belanger
Herve Souchet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inatherys
Original Assignee
Inatherys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inatherys filed Critical Inatherys
Publication of CA2992509A1 publication Critical patent/CA2992509A1/en
Application granted granted Critical
Publication of CA2992509C publication Critical patent/CA2992509C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA2992509A 2015-07-22 2016-07-21 Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases Active CA2992509C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306192.4 2015-07-22
EP15306192 2015-07-22
PCT/EP2016/067465 WO2017013230A1 (en) 2015-07-22 2016-07-21 ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
CA2992509A1 CA2992509A1 (en) 2017-01-26
CA2992509C true CA2992509C (en) 2025-02-04

Family

ID=53776520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2992509A Active CA2992509C (en) 2015-07-22 2016-07-21 Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases

Country Status (22)

Country Link
US (2) US11230605B2 (OSRAM)
EP (1) EP3325509B1 (OSRAM)
JP (1) JP6858185B2 (OSRAM)
KR (1) KR102690998B1 (OSRAM)
CN (1) CN107849136B (OSRAM)
AU (1) AU2016296321B2 (OSRAM)
CA (1) CA2992509C (OSRAM)
CY (1) CY1123941T1 (OSRAM)
DK (1) DK3325509T3 (OSRAM)
ES (1) ES2860988T3 (OSRAM)
HR (1) HRP20210393T1 (OSRAM)
HU (1) HUE053296T2 (OSRAM)
IL (1) IL257065B (OSRAM)
LT (1) LT3325509T (OSRAM)
MX (1) MX2018000569A (OSRAM)
PL (1) PL3325509T3 (OSRAM)
PT (1) PT3325509T (OSRAM)
RS (1) RS61586B1 (OSRAM)
RU (1) RU2737637C2 (OSRAM)
SI (1) SI3325509T1 (OSRAM)
SM (1) SMT202100134T1 (OSRAM)
WO (1) WO2017013230A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
FR3062213B1 (fr) 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4069745A4 (en) * 2019-11-06 2024-05-29 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING
MX2022009418A (es) * 2020-01-31 2022-08-25 Dyne Therapeutics Inc Anticuerpo del receptor anti-transferrina (tfr) y usos del mismo.
US11638761B2 (en) * 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) * 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11827702B2 (en) 2021-09-01 2023-11-28 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
TW202330601A (zh) * 2021-09-13 2023-08-01 德州大學系統董事會 ＴｆＲ抗原結合蛋白及其用途
KR20250004770A (ko) * 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
CN120282983A (zh) * 2022-12-02 2025-07-08 百奥赛图(北京)医药科技股份有限公司 抗tfr1抗体及其应用
CN120958020A (zh) 2023-03-24 2025-11-14 戴纳立制药公司 Aβ靶向蛋白和使用方法
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
BR0008758A (pt) * 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2005011082A2 (en) 2003-07-23 2005-02-03 Univeral Infusion Technology Drive motor transmission system
EP1740616B1 (en) * 2004-04-30 2011-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-tfr antibody.
US7572895B2 (en) * 2004-06-07 2009-08-11 Raven Biotechnologies, Inc. Transferrin receptor antibodies
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
EP2880059A1 (en) * 2012-08-02 2015-06-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of transferrin receptor antagonist for the treatment of thalassemia
CA2893794C (en) * 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer

Also Published As

Publication number Publication date
AU2016296321B2 (en) 2022-09-08
CY1123941T1 (el) 2022-05-27
CA2992509A1 (en) 2017-01-26
JP6858185B2 (ja) 2021-04-14
HK1256088A1 (en) 2019-09-13
KR20180028519A (ko) 2018-03-16
RU2018106364A3 (OSRAM) 2019-08-22
PL3325509T3 (pl) 2021-07-19
US11230605B2 (en) 2022-01-25
CN107849136A (zh) 2018-03-27
RU2018106364A (ru) 2019-08-22
IL257065A (en) 2018-03-29
SI3325509T1 (sl) 2021-07-30
AU2016296321A1 (en) 2018-01-25
KR102690998B1 (ko) 2024-07-31
JP2018521691A (ja) 2018-08-09
US20220119543A1 (en) 2022-04-21
EP3325509B1 (en) 2020-12-16
SMT202100134T1 (it) 2021-05-07
WO2017013230A1 (en) 2017-01-26
EP3325509A1 (en) 2018-05-30
RS61586B1 (sr) 2021-04-29
HUE053296T2 (hu) 2021-06-28
US12037408B2 (en) 2024-07-16
RU2737637C2 (ru) 2020-12-01
PT3325509T (pt) 2021-03-12
DK3325509T3 (da) 2021-03-08
CN107849136B (zh) 2022-04-01
HRP20210393T1 (hr) 2021-04-30
BR112018000650A2 (en) 2018-09-18
LT3325509T (lt) 2021-06-10
ES2860988T3 (es) 2021-10-05
US20190092870A1 (en) 2019-03-28
MX2018000569A (es) 2018-09-27
IL257065B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
CA2992509C (en) Anti-TFR antibodies and their use in the treatment of proliferative and inflammatory diseases
IL270596A (en) Antibodies containing heavy constant regions are adapted for use in cancer therapy
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
IL271221A (en) Antibodies that bind il-1beta for use in cancer therapy
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MX2022014764A (es) Anticuerpos biespecificos contra beta amiloide humana/receptor de transferrina humano y metodos de uso.
NZ732568A (en) Antibodies targeting b-cell maturation antigen and methods of use
PH12018500710A1 (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
GEP20217331B (en) Anti-tigit antibodies
TN2018000333A1 (en) Anti-tim-3 antibodies and compositions
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
GEP20217317B (en) Combination therapy for the treatment of cancer
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
HUE053128T2 (hu) Bispecifikus antitestek rák immunterápiában történõ alkalmazásra
MX2017007747A (es) Anticuerpos para il-17c.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503

EEER Examination request

Effective date: 20210503